CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 26, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY - News), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended June 30, 2006 and company highlights. “Building on our progress in the first quarter, we continued to deliver on the achievement of key milestones in the second quarter, including advances in our clinical and scientific programs and significant strengthening of our intellectual property position and pharmaceutical partnerships, while maintaining a solid financial profile with steady and recurring partner revenue,” said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. “We expect to extend this track record of execution in the second half of the year with additional progress on our clinical and pre-clinical pipelines, advancement of our next development program, continued strengthening of our leading intellectual property estate, formation of new partnerships, and sustained financial strength.”
